Tag Archives: Biogen

Congressional Report Finds FDA Ignored Agency Protocols in Approving Biogen’s Aduhelm Alzheimer’s Drug

December 30, 2022 By: Irvin Jackson

Biogen and FDA held numerous improperly documented meetings designed to drag Aduhelm through the approval process despite a lack of evidence showing the drug worked, the report found
FDA System For Approving New Drugs Found Lacking By Study

September 24, 2021 By: Irvin Jackson
Lawmakers Demand FDA Documents on Aduhelm Approval

September 03, 2021 By: Irvin Jackson
Investigation Into Alzheimer’s Drug Approval Process Requested By Multiple Entities, Including FDA

July 12, 2021 By: Irvin Jackson
Two FDA Advisory Committee Members Quit Over Controversial Approval of New Alzheimer’s Drug

June 11, 2021 By: Russell Maas
Consumer Group Calls FDA Approval of New Alzheimer’s Drug “Reckless”

June 08, 2021 By: Irvin Jackson
Public Citizen Calls For Investigation Into Collaboration Between FDA and Biogen Over New Alzheimer’s Drug

December 15, 2020 By: Irvin Jackson
Tysabri PML Risk-Minimization Strategies Working, Study Finds

September 16, 2019 By: Martha Garcia
Zinbryta Brain Inflammation Risks Outweigh Benefits: EMA

May 22, 2018 By: Irvin Jackson
Zinbryta Risks Prevented Use As MS Drug, Despite Effectiveness of Treatment: Report

April 25, 2018 By: Irvin Jackson

Cartiva Recall Lawsuit Alleges Failed Toe Implant Had To Be Surgically Removed Days Before Manufacturer Acknowledged Defect (Posted 4 days ago)

Although there were reports of problems with Cartiva implants for years, a recently filed lawsuit alleges the manufacturer delayed issuing a recall until October 2024.

MDL Judge Schedules Ozempic Lawsuit Status Conferences Throughout 2025 (Posted 5 days ago)

With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.

Valsartan Bellwether Lawsuit Over Cancer Caused by Recalled Blood Pressure Drug Set for September 8, 2025 (Posted 6 days ago)

The first Valsartan bellwether trial will begin on September 8, 2025, involving allegations that the generic hypertension drug contained toxic chemicals that resulted in a liver cancer diagnosis.

Tag Archives: Biogen

Congressional Report Finds FDA Ignored Agency Protocols in Approving Biogen’s Aduhelm Alzheimer’s Drug

FDA System For Approving New Drugs Found Lacking By Study

Lawmakers Demand FDA Documents on Aduhelm Approval

Investigation Into Alzheimer’s Drug Approval Process Requested By Multiple Entities, Including FDA

Two FDA Advisory Committee Members Quit Over Controversial Approval of New Alzheimer’s Drug

Consumer Group Calls FDA Approval of New Alzheimer’s Drug “Reckless”

Public Citizen Calls For Investigation Into Collaboration Between FDA and Biogen Over New Alzheimer’s Drug

Tysabri PML Risk-Minimization Strategies Working, Study Finds

Zinbryta Brain Inflammation Risks Outweigh Benefits: EMA

Zinbryta Risks Prevented Use As MS Drug, Despite Effectiveness of Treatment: Report

More Top Stories

Review A Case